Drug recall
Drug recall notice for all Akorn drug productsPharmacy news
Find pharmacy-related safety alerts, drug recall and new generic drug announcements, and other medication information.
Pharmacy news bulletins available on the portal
For a list of pharmacy news bulletins, pharmacists may sign in to the
The Inflation Reduction Act (IRA) became law on August 16, 2022 and includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government
Drug recalls
Additional notifications
Information about the launch of generic Farxiga
Effective on the date of launch, Jan. 6, 2024, generic Farxiga (dapagliflozin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Farxiga will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Xigduo XR
Effective on the date of launch, Jan. 6, 2024, generic Xigduo XR (dapagliflozin-metformin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Xigduo XR will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Risperdal Consta
Effective on the date of launch, Dec. 16, 2023, generic Risperdal Consta (risperidone extended release) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Risperdal Consta will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Forteo
Effective on the date of launch, Nov. 25, 2023, generic Forteo (teriparatide) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Forteo will continue to be covered with prior authorization and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Symbicort HFA inhaler
Effective on the date of launch, Jan. 1, 2024, generic Symbicort HFA inhaler (budesonide/formoterol inhaler) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans (excluding Value PDP). Brand-name Symbicort HFA inhaler will continue to be covered (excluding Value PDP) and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Breo Ellipta
Effective on the date of launch, Jan. 1, 2024, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Breo Ellipta will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Spiriva with HandiHaler
Effective on the date of launch, Jan. 1, 2024, generic Spiriva with HandiHaler (tiotropium bromide) is not covered or may require step therapy through the brand on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Spiriva with HandiHaler will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Alphagan P 0.1%
Effective on the date of launch, Sept. 9, 2023, generic Alphagan P 0.1% (brimonidine tartrate) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Alphagan P 0.1% will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Advair HFA
Effective March 4, 2023, generic Advair HFA (fluticasone propionate/salmeterol) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug plans (excluding Lean National 5), Medicare Part D plans (excluding Basic and Value prescription drug plans) and commercial plans. Brand-name Advair HFA will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Mitigare
Effective Jan. 1, 2023, generic Mitigare (colchicine capsule) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Mitigare will continue to be covered and can be filled for patients.
Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Vascepa
Effective Jan. 1, 2023, generic Vascepa (icosapent) is not covered or may require step therapy on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Vascepa will continue to be covered and can be filled for patients.
Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Formulary changes for Revlimid
Lenalidomide, the generic version of Revlimid®, is covered by Humana with a prior authorization and will remain covered in 2023. Effective Jan. 1, 2023, Humana Medicare plans will no longer cover Revlimid. If the generic version is not available at your patient’s pharmacy, please include this information in your coverage exception request. We have notified your patients who had a claim for Revlimid in 2022 about this formulary change.
Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Restasis
Effective Feb. 12, 2022, generic Restasis (cyclosporine) is not covered or may require prior authorization on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Restasis will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Combigan
Effective Jan. 22, 2022, generic Combigan (brimonidine-timolol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Combigan will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the use of ivermectin and COVID-19
The Centers for Disease Control and Prevention has released a health advisory regarding the rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of products containing ivermectin to prevent and treat COVID-19.
Please see this
Updates could mean new requirements for Humana members
Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.
These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.
Information about the launch of generic Durezol
Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of authorized generic insulin aspart and insulin aspart mix
Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Med-Edit update notification
As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.